IgLON5 antibody
Neurological accompaniments and outcomes in 20 patients
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 7, 2017
- Accepted in final form June 8, 2017
- First Published July 18, 2017.
Author Disclosures
- Josephe A. Honorat, MD, PhD,
- Lars Komorowski, PhD,
- Keith A. Josephs, MD,
- Kai Fechner, MEng,
- Erik K. St Louis, MD, MS,
- Shannon R. Hinson, PhD,
- Sabine Lederer,
- Neeraj Kumar, MD,
- Avi Gadoth, MD,
- Vanda A. Lennon, MD, PhD,
- Sean J. Pittock, MD and
- Andrew McKeon, MD
- Josephe A. Honorat, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lars Komorowski, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Employee of EUROIMMUN AG.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Keith A. Josephs, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NIA (R01-AG037491), PI NIH/NINDS (R01-NS89757), PI NIH/NINDS (R21-NS94684), PI NIH/NIDCD (R01-DC012519), Co-I
NONE
The Dana Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Kai Fechner, MEng,
NONE
NONE
NONE
NONE
NONE
NONE
EUROIMMUN AG, Director Division Immunofluorescence Diagnostics, 11 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Erik K. St Louis, MD, MS,
Inspire, Inc. - serve on Data Safety and Monitoring Board and Adverse Events Adjudication Committee for a randomized-controlled treatment trial of an investigational device for sleep apnea.
NONE
NONE
AAN Continuum Editorial Board Member; Guest Co-Editor, AAN Continuum Epilepsy and Sleep volumes
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Axovant, Merck, and Sunovion, Inc.
Research Support from Mayo Clinic CTSA through grant number UL1 TR000135 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shannon R. Hinson, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sabine Lederer,
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun Medizinische Labordiagnostika AG, medical technical assistant, since 12 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Neeraj Kumar, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Avi Gadoth, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vanda A. Lennon, MD, PhD,
NONE
NONE
NONE
NONE
Vanda Lennon receives royalties from RSR/Kronus for sale of aquaporin-4 autoantibody testing kits and for commercial aquaporin-4 autoantibody testing performed outside Mayo Clinic.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH R01-NS065829,?CNS Demyelinating Autoimmunity Targeting Water Channel Complexes?. Principal Investigator: S.J. Pittock Co-Investigator: V.A. Lennon Years: 2010-2015
NONE
NONE
NONE
1) RSR/Kronus for sale of aquaporin-4 autoantibody testing kits. 2) Non-Mayo sites performing “home brew” diagnostic testing for aquaporin-4 autoantibody.
Dr. Lennon has a potential financial interest in the technologies listed below: “Aquaporin-4 as an aid for cancer diagnosis”.
NONE
NONE
NONE
- Sean J. Pittock, MD and
NONE
NONE
NONE
NONE
Dr. Pittock and Mayo Clinic have a financial interest in patents (#12/678,350 filed 2010 and #12/573,942 filed 2008) that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker;
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
NONE
NONE
Dr Pittock has received research funding from Grifols, Medimmune and Alexion.
RO1 NS065829-01
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew McKeon, MD
NONE
NONE
NONE
NONE
Patent applications pending: GFAP and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders
NONE
NONE
Grifols Medimmune Euroimmun No personal compensation received for these activities
NONE
NONE
NONE
Medimmune, Inc Euroimmun
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Laboratory Medicine and Pathology (J.A.H., S.R.H., V.A.L., S.J.P., A.M.), Department of Neurology (K.A.J., E.K.S.L., N.K., A.G., V.A.L., S.J.P., A.M.), Department of Medicine (E.K.S.L.), Department of Immunology (V.A.L.), and Center for Sleep Medicine (E.K.S.L.), College of Medicine, Mayo Clinic, Rochester, MN; and Institute of Experimental Immunology (L.K., K.F., S.L.), Euroimmun AG, Lubeck, Germany.
- Correspondence to Dr. McKeon: mckeon.andrew{at}mayo.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Clinical manifestations of the anti-IgLON5 diseaseCarles Gaig, Francesc Graus, Yarko Compta et al.Neurology, April 05, 2017 -
Article
Paraneoplastic neuronal intermediate filament autoimmunityEati Basal, Nicholas Zalewski, Thomas J. Kryzer et al.Neurology, October 03, 2018 -
Article
DPPX potassium channel antibodyFrequency, clinical accompaniments, and outcomes in 20 patientsWilliam Oliver Tobin, Vanda A. Lennon, Lars Komorowski et al.Neurology, October 15, 2014 -
Article
Anti-IgLON5 DiseaseA New Bulbar-Onset Motor Neuron Mimic SyndromeJana Werner, Ilijas Jelcic, Esther Irene Schwarz et al.Neurology: Neuroimmunology & Neuroinflammation, February 02, 2021